Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552704 · ClinicalTrials.gov registry record · Phase 1
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
A Phase 1 study, sponsored by Tianhong Li.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04552704 is a Phase 1 study that was terminated before completion, run by Tianhong Li. The registered enrollment target is 3 participants.
The verdict
NCT04552704, a Phase 1 study, was terminated before completion, sponsored by Tianhong Li.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase I/II trial investigates the side effects and how well CD24Fc works in treating immune related adverse events in patients with solid tumors that have spread to other places in the body (advanced). CD24Fc may prevent autoimmune reactions due to the tissue damage induced by cancer treatment. CD24Fc binds to injured cell components and prevents inflammatory responses. CD24Fc also acts to turn off the immune system after it has been activated ("immune checkpoint"). Adding CD24Fc to standard treatment may shorten the recovery time and reduce the severity of side effects from immunotherapy.
Interventions
- DRUG Placebo Administration
- BIOLOGICAL CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2022-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04552704
The ClinicalTrials.gov registry entry for NCT04552704 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tianhong Li, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Administration is the first listed.
NCT04552704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04552704 about?
NCT04552704 is a clinical study titled "CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study". This phase I/II trial investigates the side effects and how well CD24Fc works in treating immune related adverse events in patients with solid tumors that have spread to other places in the body (advanced). CD24Fc may prevent autoimmune reactions due to the tissue damage induced by cancer treatment....
What is the current status of trial NCT04552704?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-10-30. Estimated completion is 2022-01-26.
What interventions are being tested in trial NCT04552704?
The interventions under investigation include: Placebo Administration (DRUG), CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc (BIOLOGICAL).
Who is sponsoring clinical trial NCT04552704?
This trial is sponsored by Tianhong Li, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.